Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments - New Drug Application 220359, for camizestrant tablets; Supplemental New Drug Application (sNDA) 218197 / S-004, for Truqap (capivasertib) tablets | Federal Regulations · Congress.wiki